Major Finding: “Real-world” multiple sclerosis patients treated with natalizumab had rates of adverse events and reduction in relapses similar to those observed in patients in phase III trials.
Data Source: Ongoing postmarketing observational study of 1,011 patients.
Disclosures: Study funded by Biogen Idec Inc.; Dr. Trojano, consulting or speaking fees from Biogen Idec and research funding from Merck Serono.
PREVIEW